Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > load up load up
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(101)
•••
Comment by Quentin30on May 26, 2023 4:34pm
130 Views
Post# 35466514

RE:RE:load up load up

RE:RE:load up load upNO evidence... LOL... Pfizer has walked away...  Matt has signalled that we may not have a CPI - he's been priming us for this... so it's not a shock...

and sure I repeat myself, are you beginning to see the pattern with ONCY yet..?  How well have the pumpers been doing..

A couple of weeks ago, I stated that the price goes up towards news and reaches a high two days prior, before tanking on news release... and voila, once again... history repeats...

just because I repeat myself, does not make it less true... 

WHY would I wanna do this... to save others from the same mistake I made in listening to the fanstasists years ago.. and at one point being 95% down... first decent chance I have of getting out... I'm gone don't you worry... until then... I'll say it as I see it. As it is...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities